Barclays PLC (ZNTL) discloses 2.26M-share, 3.17% stake in Zentalis

Rhea-AI Filing Summary

Barclays PLC filed an amended Schedule 13G reporting its beneficial ownership in Zentalis Pharmaceuticals Inc. common stock. Barclays reports beneficial ownership of 2,263,328 shares of common stock, representing 3.17% of the class as of June 30, 2026.

Within this total, Barclays has 2,046,932 shares with sole voting and dispositive power and 216,396 shares with shared voting and dispositive power. The filing notes that Barclays now holds 5 percent or less of the class, and identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as relevant subsidiaries.

Key Figures

Shares beneficially owned: 2,263,328 shares Percent of class: 3.17% Sole voting and dispositive power: 2,046,932 shares +3 more

6 metrics

Shares beneficially owned 2,263,328 shares Beneficial ownership of Zentalis common stock reported by Barclays PLC as of June 30, 2026

Percent of class 3.17% Percentage of Zentalis common stock class beneficially owned by Barclays PLC

Sole voting and dispositive power 2,046,932 shares Shares over which Barclays PLC has sole power to vote and dispose

Shared voting and dispositive power 216,396 shares Shares over which Barclays PLC has shared power to vote and dispose

Ownership threshold status 5 percent or less Barclays PLC indicates ownership of 5 percent or less of the class

Signature date 08/14/2026 Date the amended Schedule 13G was signed by Ramya Rao, Director

Key Terms

beneficially owned, Sole Voting Power, Shared Voting Power, Sole Dispositive Power, +2 more

6 terms

beneficially owned financial

"Amount beneficially owned: 2263328"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"Sole Voting Power 2,046,932.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

Shared Voting Power financial

"Shared Voting Power 216,396.00"

Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.

Sole Dispositive Power financial

"Sole Dispositive Power 2,046,932.00"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

Shared Dispositive Power financial

"Shared Dispositive Power 216,396.00"

parent holding company regulatory

"If a parent holding company has filed this schedule"

FAQ

What percentage of ZNTL common stock does Barclays PLC report owning?

Barclays PLC reports beneficial ownership of 3.17% of Zentalis Pharmaceuticals Inc. (ZNTL) common stock. This corresponds to 2,263,328 shares as of June 30, 2026, according to the amended Schedule 13G filing.

How many ZNTL shares does Barclays PLC beneficially own?

Barclays PLC reports beneficial ownership of 2,263,328 ZNTL shares. Of these, 2,046,932 shares carry sole voting and dispositive power, and 216,396 shares carry shared voting and dispositive power under the Schedule 13G/A.

Does Barclays PLC still own 5% or more of ZNTL stock?

No. Barclays PLC states that it has ownership of 5 percent or less of Zentalis Pharmaceuticals Inc. common stock. The filing quantifies its current beneficial ownership at 3.17% of the class as of June 30, 2026.

What are Barclays PLC’s sole and shared voting powers in ZNTL?

Barclays PLC reports 2,046,932 shares with sole voting and dispositive power and 216,396 shares with shared voting and dispositive power in ZNTL. These figures together total 2,263,328 beneficially owned shares.

Which subsidiaries of Barclays are linked to the ZNTL holdings?

The filing identifies Barclays Bank PLC, Barclays Capital Inc, and Barclays Capital Securities Ltd as subsidiaries related to the Zentalis Pharmaceuticals Inc. holdings reported on the Schedule 13G/A by Barclays PLC.

When was the amended ownership report for ZNTL by Barclays PLC signed?

The amended Schedule 13G for Zentalis Pharmaceuticals Inc. was signed on August 14, 2026 by Ramya Rao, Director at Barclays PLC. The reported ownership information is stated as of June 30, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 07:12 PM Accepted by SEC EDGAR 08/13/2026 - 07:11 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

ZENTALIS PHARMACEUTICALS INC

(Name of Issuer)

COMMON-STOCK

(Title of Class of Securities)

98943L107

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 98943L107

1

Names of Reporting Persons

Barclays PLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED KINGDOM

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,046,932.00
6	Shared Voting Power 216,396.00
7	Sole Dispositive Power 2,046,932.00
8	Shared Dispositive Power 216,396.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,263,328.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

3.17 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: ZENTALIS PHARMACEUTICALS INC
(b)	Address of issuer's principal executive offices: 10275 Science Center Drive
Item 2.
(a)	Name of person filing: Barclays PLC
(b)	Address or principal business office or, if none, residence: 1 Churchill Place, London - E14 5HP
(c)	Citizenship: X0
(d)	Title of class of securities: COMMON-STOCK
(e)	CUSIP No.: 98943L107
Item 4.	Ownership
(a)	Amount beneficially owned: 2263328
(b)	Percent of class: 3.17 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 2046932
	(ii) Shared power to vote or to direct the vote: 216396
	(iii) Sole power to dispose or to direct the disposition of: 2046932
	(iv) Shared power to dispose or to direct the disposition of: 216396
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. Barclays Bank PLC, Barclays Capital Inc, Barclays Capital Securities Ltd
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Barclays PLC

Signature:	Ramya Rao
Name/Title:	Director
Date:	08/14/2026